Genocea Biosciences has raised $30 million in a Series C financing round to advance its T-cell vaccines for infectious diseases. With the close of this financing round, the clinical-stage company has landed a total of $76 million in equity financing to date.
The Bill and Melinda Gates Foundation has been renowned for its dedication to public health and vaccine research; now it has added more talent to its roster with new heads for two of its three main
Over the past two years Novartis ($NVS) has managed to steer clear of the R&D breakdown that has afflicted such rivals as Pfizer ($PFE) and Sanofi ($SNY), pushing them to upend pipelines and
Word in the Swiss media is that the Gates Foundation is trying to woo away Novartis' ($NVS) Trevor Mundel, aiming to install him as executive director of global health. Mundel has headed up Novartis'
Restructuring under the gun of new generics and after being slammed by regulatory defeats, Novartis is bidding adieu to James Shannon, its chief of global drug development. In his place Novartis has